{"id":523173,"date":"2021-08-04T10:35:06","date_gmt":"2021-08-04T14:35:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/"},"modified":"2021-08-04T10:35:06","modified_gmt":"2021-08-04T14:35:06","slug":"dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/","title":{"rendered":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL<\/b><\/p>\n<p>HYDERABAD, India &amp; PRINCETON, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDr. Reddy\u2019s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as \u201cDr. Reddy\u2019s\u201d), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy\u2019s will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg\/mL, to BioDelivery Sciences International, Inc. (BDSI).\n<\/p>\n<p>\nUnder the terms of agreement, Dr.Reddy\u2019s will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing. Further, Dr. Reddy\u2019s is eligible to receive event based, sales based milestones and quarterly earn-out payments.\n<\/p>\n<p>\nELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.\n<\/p>\n<p>\nThe closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.\n<\/p>\n<p><b><span class=\"bwuline\">Erez Israeli, Chief Executive Officer of Dr. Reddy\u2019s Laboratories, said:<\/span><\/b> \u201cELYXYB reaffirmed our commitment to innovation and to develop meaningfully differentiated products that address significant unmet needs of patients. ELYXYB is an oral solution dosage form which makes it convenient for patients to take it immediately upon emergence of migraine attacks. Further, we are confident in BDSI\u2019s expertise and believe in their ability to realize the full potential of ELYXYB\u201d\n<\/p>\n<p><b>INDICATION AND USAGE<\/b><\/p>\n<p>\nELYXYB is indicated in adults for the acute treatment of migraine with or without aura.\n<\/p>\n<p>\nLimitations of Use:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nELYXYB is not indicated for the preventive treatment of migraine.\n<\/li>\n<\/ul>\n<p class=\"bwalignc\"><b>IMPORTANT SAFETY INFORMATION:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS<\/b><\/p>\n<p class=\"bwcellpmargin\"><b><span class=\"bwuline\">Cardiovascular Thrombotic Events <\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use<i> [see Warnings and Precautions (5.1) of Prescribing Information].<\/i><\/b><\/li>\n<li><b>ELYXYB is contraindicated in the setting of coronary artery bypass graft (CABG) surgery <i>[see Contraindications (4) and Warnings and Precautions (5.1) of Prescribing Information].<\/i><\/b><\/li>\n<\/ul>\n<p class=\"bwcellpmargin\"><b><span class=\"bwuline\">Gastrointestinal Bleeding, Ulceration, and Perforation<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and\/or GI bleeding are at greater risk for serious (GI) events <i>[see Warnings and Precautions (5.2) of Prescribing Information].<\/i><\/b><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nELYXB is contraindicated in patients with:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nKnown hypersensitivity to celecoxib, any components of the drug product, or sulfonamides\n<\/li>\n<li>\nHistory of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs\n<\/li>\n<li>\nIn the setting of CABG surgery\n<\/li>\n<\/ul>\n<p>\nTo minimize the potential risk for an adverse cardiovascular (CV) event in NSAID-treated patients, use ELYXYB for the fewest number of days per month as needed, based on individual treatment goals. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.\n<\/p>\n<p>\nAvoid the use of ELYXYB in patients with a recent myocardial infarction (MI) unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ELYXYB is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.\n<\/p>\n<p>\nNSAIDs, including ELYXYB, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with celecoxib. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.\n<\/p>\n<p>\nAvoid the use of ELYXYB in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ELYXYB is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.\n<\/p>\n<p>\nElevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including ELYXYB.\n<\/p>\n<p>\nLong-term administration of NSAIDs, including celecoxib, the active ingredient in ELYXYB, has resulted in renal papillary necrosis and other renal injury.\n<\/p>\n<p>\nNo information is available from controlled clinical studies regarding the use of celecoxib in patients with severe renal impairment. The renal effects of celecoxib may hasten the progression of renal dysfunction in patients with preexisting renal disease.\n<\/p>\n<p>\nOveruse of acute migraine drugs (e.g., ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month), including ELYXYB, may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.\n<\/p>\n<p>\nNSAIDs, including ELYXYB, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.\n<\/p>\n<p>\nMost common adverse reaction (at least 3% and greater than placebo) is dysgeusia.\n<\/p>\n<p>\nThese are not all the side effects associated with ELYXYB.\n<\/p>\n<p>\nPlease see Patient Information, Instructions For Use, Medication Guide and Full Prescribing Information for ELYXYB.\n<\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F212157s002lbl.pdf&amp;esheet=52471652&amp;newsitemid=20210804005769&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F212157s002lbl.pdf&amp;index=1&amp;md5=0eecdf790cb9bdb10ad7375fece5a8e7\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212157s002lbl.pdf<\/a><\/p>\n<p><b>About Dr. Reddy\u2019s: <\/b>Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses &#8211; Pharmaceutical Services &amp; Active Ingredients, Global Generics and Proprietary Products \u2013 Dr. Reddy\u2019s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy\u2019s operates in markets across the globe. Our Major markets include \u2013 USA, India, Russia &amp; CIS countries, and Europe. For more information, log on to: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=52471652&amp;newsitemid=20210804005769&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=2&amp;md5=74d204450a41d7bfc7f6eb0a46b1f01b\">www.drreddys.com<\/a><\/p>\n<p><b>Disclaimer<\/b>: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, or &#8220;continue&#8221; and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency \/ severity of insured loss events (ii) mortality and morbidity levels and trends, (iii)\n<\/p>\n<p>\nchanging levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements&#8221; sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.\u201d\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210804005769\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210804005769\/en\/<\/a><\/span><\/p>\n<p><b>INVESTOR RELATIONS<br \/>\n<\/b><br \/>AMIT AGARWAL<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amita@drreddys.com\">amita@drreddys.com <\/a><\/p>\n<p><b>MEDIA RELATIONS<br \/>\n<\/b><br \/>USHA IYER<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ushaiyer@drreddys.com\">ushaiyer@drreddys.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States India North America Asia Pacific New Jersey<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210804005769\/en\/485181\/3\/DrR_Logo_Primary_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL HYDERABAD, India &amp; PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; Dr. Reddy\u2019s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as \u201cDr. Reddy\u2019s\u201d), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy\u2019s will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg\/mL, to BioDelivery Sciences International, Inc. (BDSI). Under the terms of agreement, Dr.Reddy\u2019s will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing. Further, Dr. Reddy\u2019s is eligible to receive event based, sales &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-523173","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL HYDERABAD, India &amp; PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; Dr. Reddy\u2019s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as \u201cDr. Reddy\u2019s\u201d), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy\u2019s will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg\/mL, to BioDelivery Sciences International, Inc. (BDSI). Under the terms of agreement, Dr.Reddy\u2019s will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing. Further, Dr. Reddy\u2019s is eligible to receive event based, sales &hellip; Continue reading &quot;Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-04T14:35:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\\\/mL\",\"datePublished\":\"2021-08-04T14:35:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/\"},\"wordCount\":1438,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/\",\"name\":\"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\\\/mL - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-04T14:35:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\\\/mL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL - Market Newsdesk","og_description":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL HYDERABAD, India &amp; PRINCETON, N.J.&#8211;(BUSINESS WIRE)&#8211; Dr. Reddy\u2019s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter known as \u201cDr. Reddy\u2019s\u201d), announced today that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy\u2019s will sell its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg\/mL, to BioDelivery Sciences International, Inc. (BDSI). Under the terms of agreement, Dr.Reddy\u2019s will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing. Further, Dr. Reddy\u2019s is eligible to receive event based, sales &hellip; Continue reading \"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-04T14:35:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL","datePublished":"2021-08-04T14:35:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/"},"wordCount":1438,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/","name":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-04T14:35:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210804005769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-entry-into-definitive-agreement-with-biodelivery-sciences-international-inc-to-sell-its-u-s-and-canada-territory-rights-for-elyxyb-celecoxib-oral-soluti\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Reddy\u2019s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg\/mL"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=523173"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523173\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=523173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=523173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=523173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}